Introduction: Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established.
Case presentation: We report the case of a 70-year-old man with undifferentiated prostate cancer and lymph node metastases. Following the patient's progression after platinum-based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay.
Conclusion: Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.
Keywords: chemotherapy; docetaxel; prostate cancer; quality of life; undifferentiated carcinoma.
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.